ATE394097T1 - Verfahren zur verabreichung von buprenorphin zur behandlung von depression - Google Patents

Verfahren zur verabreichung von buprenorphin zur behandlung von depression

Info

Publication number
ATE394097T1
ATE394097T1 AT03721427T AT03721427T ATE394097T1 AT E394097 T1 ATE394097 T1 AT E394097T1 AT 03721427 T AT03721427 T AT 03721427T AT 03721427 T AT03721427 T AT 03721427T AT E394097 T1 ATE394097 T1 AT E394097T1
Authority
AT
Austria
Prior art keywords
depression
buprenorphine
administration
treatment
patients suffering
Prior art date
Application number
AT03721427T
Other languages
English (en)
Inventor
Robert Kaiko
Ramiro Sanchez
Original Assignee
Euro Celtique Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Euro Celtique Sa filed Critical Euro Celtique Sa
Application granted granted Critical
Publication of ATE394097T1 publication Critical patent/ATE394097T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Organic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
AT03721427T 2002-03-20 2003-03-20 Verfahren zur verabreichung von buprenorphin zur behandlung von depression ATE394097T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US36635802P 2002-03-20 2002-03-20

Publications (1)

Publication Number Publication Date
ATE394097T1 true ATE394097T1 (de) 2008-05-15

Family

ID=28454789

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03721427T ATE394097T1 (de) 2002-03-20 2003-03-20 Verfahren zur verabreichung von buprenorphin zur behandlung von depression

Country Status (12)

Country Link
US (1) US20030181475A1 (de)
EP (1) EP1485051B1 (de)
JP (1) JP2005528359A (de)
AT (1) ATE394097T1 (de)
AU (1) AU2003224742A1 (de)
CY (1) CY1108217T1 (de)
DE (1) DE60320770D1 (de)
DK (1) DK1485051T3 (de)
ES (1) ES2305457T3 (de)
PT (1) PT1485051E (de)
SI (1) SI1485051T1 (de)
WO (1) WO2003079945A1 (de)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5968547A (en) 1997-02-24 1999-10-19 Euro-Celtique, S.A. Method of providing sustained analgesia with buprenorphine
EP1572167B1 (de) 2002-12-13 2008-07-09 Euro-Celtique S.A. Transdermales buprenorphin-dosierschema zwecks schmerzstillung
EP1913938A1 (de) * 2002-12-13 2008-04-23 Euro-Celtique S.A. Transdermales Dosierungsschema für Buprenorphin zur Schmerzstillung
MY141815A (en) 2003-04-30 2010-06-30 Purdue Pharma Lp Tamper-resistant transdermal dosage form comprising an active agent component and an adverse agent component at the distal site of the active agent layer
US8790689B2 (en) 2003-04-30 2014-07-29 Purdue Pharma L.P. Tamper resistant transdermal dosage form
KR100829492B1 (ko) 2003-07-25 2008-05-19 유로-셀띠끄 소시에떼 아노님 의존성 금단의 치료
DE10340428B4 (de) * 2003-09-02 2015-02-12 Acino Ag Opioides Analgetikum enthaltende transdermale Formulierung
FR2865650B1 (fr) * 2004-01-30 2008-06-13 Biocortech Utilisation du 14,15 dihydro 20,21-dinoreburnamenin14-ol pour traiter et/ou prevenir les depressions majeures et les desordres du cycle veille-sommeil
DE102004045599A1 (de) * 2004-09-17 2006-03-23 Grünenthal GmbH System zur sequentiellen, transdermalen Verabreichung von systemisch wirksamen Substanzen
DE102005007859A1 (de) * 2005-02-21 2006-08-24 Lts Lohmann Therapie-Systeme Ag Vefahren für eine medikamentöse Kombinations-Behandlung, sowie hierfür geeignete Arzneimittel-Kombinationen
DE102006011340A1 (de) * 2006-03-09 2007-09-20 Grünenthal GmbH Wirkstoffhaltige Pflaster mit verbesserter Handhabung
AU2010326676B2 (en) 2009-12-04 2013-03-14 Alkermes Pharma Ireland Limited Morphinan derivatives for the treatment of drug overdose
FI3446565T3 (fi) 2010-08-23 2024-01-30 Alkermes Pharma Ireland Ltd Menetelmiä antipsykoottisten lääkkeiden aiheuttaman painonnousun hoitamiseksi
WO2013042054A1 (en) * 2011-09-19 2013-03-28 Carmel - Haifa University Economic Corporation Ltd. Buprenorphine for the treatment of acute suicidality
CA2858808C (en) * 2011-12-15 2017-04-18 Alkermes Pharma Ireland Limited Samidorphan (alks 33) in combination with opioid agonists
US10195191B2 (en) 2011-12-15 2019-02-05 Alkermes Pharma Ireland Limited Opioid agonist antagonist combinations
US9211293B2 (en) 2011-12-15 2015-12-15 Alkermes Pharma Ireland Limited Opioid agonist antagonist combinations
EP2790702B1 (de) * 2011-12-15 2020-04-01 Alkermes Pharma Ireland Limited Zusammensetzungen aus buprenorphin und mu-opioid-rezeptorantagonisten
US9656961B2 (en) 2013-05-24 2017-05-23 Alkermes Pharma Ireland Limited Methods for treating depressive symptoms
EP3004114B1 (de) 2013-05-24 2019-12-25 Alkermes Pharma Ireland Limited Morphan- und morphinananaloga und verfahren zur verwendung
RU2679661C1 (ru) * 2013-12-20 2019-02-12 Х. Лундбекк А/С Применение антагониста опиоидных рецепторов с k-активностью и вортиоксетина для лечения депрессивного расстройства с меланхолическими признаками
EP4243768A1 (de) 2020-11-12 2023-09-20 Alkermes Pharma Ireland Limited Mehrschichttablette mit sofortiger freisetzung

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4806341A (en) * 1985-02-25 1989-02-21 Rutgers, The State University Of New Jersey Transdermal absorption dosage unit for narcotic analgesics and antagonists and process for administration
US5026556A (en) * 1988-11-10 1991-06-25 Norwich Eaton Pharmaceuticals, Inc. Compositions for the transdermal delivery of pharmaceutical actives
US4956171A (en) * 1989-07-21 1990-09-11 Paco Pharmaceutical Services, Inc. Transdermal drug delivery using a dual permeation enhancer and method of performing the same
US5240711A (en) * 1989-11-29 1993-08-31 Lts Lohmann Therapie-Systeme Gmbh & Co. Kg Transdermal therapeutic system comprising as active component buprenorphine
CA2062828C (en) * 1990-04-24 1996-04-16 Osafumi Hidaka Pharmaceutical plasters
US5069909A (en) * 1990-06-20 1991-12-03 Cygnus Therapeutic Systems Transdermal administration of buprenorphine
US5512593A (en) * 1993-03-02 1996-04-30 John S. Nagle Composition and method of treating depression using natoxone or naltrexone in combination with a serotonin reuptake inhibitor
US5613958A (en) * 1993-05-12 1997-03-25 Pp Holdings Inc. Transdermal delivery systems for the modulated administration of drugs
ES2177962T3 (es) * 1996-03-25 2002-12-16 Lohmann Therapie Syst Lts Sistema de administracion transdermica de reducido espesor de aplicacion y elevada flexibilidad, y proceso de fabricacion del mismo.
US6787149B1 (en) * 1996-12-12 2004-09-07 El Khoury And Stein Ltd. Topical application of opioid analgesic drugs such as morphine
US5968547A (en) * 1997-02-24 1999-10-19 Euro-Celtique, S.A. Method of providing sustained analgesia with buprenorphine
US5900420A (en) * 1997-06-19 1999-05-04 Cole; William L. Method for treating chronic fatigue syndrome and fibromyalgia with buprenorphine
DE19738855C2 (de) * 1997-09-05 2001-01-04 Lohmann Therapie Syst Lts Transdermales therapeutisches System mit haftklebender Reservoirschicht und unidirektional elastischer Rückschicht
DE19746191C2 (de) * 1997-10-18 2000-05-18 Lohmann Therapie Syst Lts Verfahren zur Anwendung eines Wirkstoff enthaltenden Pflasters zur Bekämpfung oder Linderung einer Sucht
US6242456B1 (en) * 1998-03-09 2001-06-05 Trustees Of Tufts College Treatment of stereotypic, self-injurious and compulsive behaviors in man and animals using antagonists of NMDA receptors
DE19840758A1 (de) * 1998-09-07 2000-03-09 Liedtke Pharmed Gmbh Systemische Therapie von Schmerz- und depressiver Befindlichkeit

Also Published As

Publication number Publication date
AU2003224742A1 (en) 2003-10-08
CY1108217T1 (el) 2014-02-12
EP1485051A4 (de) 2006-05-24
EP1485051A1 (de) 2004-12-15
US20030181475A1 (en) 2003-09-25
SI1485051T1 (sl) 2008-10-31
DK1485051T3 (da) 2008-09-08
PT1485051E (pt) 2008-07-09
EP1485051B1 (de) 2008-05-07
WO2003079945A1 (en) 2003-10-02
DE60320770D1 (de) 2008-06-19
ES2305457T3 (es) 2008-11-01
JP2005528359A (ja) 2005-09-22

Similar Documents

Publication Publication Date Title
CY1108217T1 (el) Μεθοδος χορηγησης βουπρενορφινης για τη θεραπεια της καταθλιψης
IS8187A (is) Meðferð á fráhvarfseinkennum
ATE399553T1 (de) Pharmazeutische zusammensetzungen mit dextromethorphan und chinidin zur behandlung von neurologischen erkrankungen
ATE380548T1 (de) Verwendung von p53 inhibitoren zur behandlung von nebenerscheinungen bei der krebstherapie
ATE265213T1 (de) Noribogain zur behandlung von schmerzen und drogenabhängigkeit
HRP20080146T3 (en) Preoperative treatment of post operative pain
ATE453402T1 (de) Verwendung von serp-1 in kombination mit einem immunosuppressor zur behandlung von arthritis
ATE310509T1 (de) Methode zur behandlung eines analgesiebedürftigen patienten
ATE484280T1 (de) Verwendung der kombination aus temozolomid und tnf-alpha zur behandlung von glioblastoma
EP1795189A3 (de) Verfahren zur Verabreichung von Buprenorphin zur Behandlung von Depression
DE69733321D1 (de) Olanzapine zur behandlung von drogenmissbrauch
DE60316927D1 (de) Verwendung von devazepide als schmerzmittel

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1485051

Country of ref document: EP